House committee passes FDA user fee reauthorization bill in unanimous vote

The House Energy and Commerce Committee on June 7 unanimously passed a bill to reauthorize the Food and Drug Administration's user fee program, the Washington Examiner reports.

The committee, which passed the FDA Reauthorization Act in a 54-0 vote, now advances the bill to the House. The legislation seeks to reauthorize the user fee program, which allows the Food and Drug Administration to collect fees from drug or devicemakers for new product applications. The agency uses these funds to hire more staff and accelerate the approval process, according to the report.

The committee also approved an additional amendment to the bill that would require the FDA to regulate device accessories. Another amendment would establish pilot projects to ensure device reliability, safety and active surveillance data.

The user fee program must be renewed every five years. As the current program expires at the end of September, lawmakers must approve the final bill before the August recess, according to the Washington Examiner.

More articles on supply chain:

5 latest FDA approvals

7 drugmakers in the headlines

4 ways hospitals can lower inpatient drug costs

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Webinars

Featured Whitepapers